Literature DB >> 25545952

Response to Re: A pilot study of an acupuncture protocol to improve visual function in retinitis pigmentosa patients.

Ava K Bittner1, Andy Rosenfarb, Jeff Gould, Gislin Dagnelie.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25545952      PMCID： PMC4476632          DOI： 10.1111/cxo.12243

Source DB:  PubMed          Journal:  Clin Exp Optom        ISSN： 0816-4622            Impact factor:   2.742


× No keyword cloud information.
  6 in total

1.  The use of acupuncture in ophthalmology.

Authors:  S Wong; R Ching
Journal:  Am J Chin Med       Date:  1980 Spring-Summer       Impact factor: 4.667

2.  Effects of electroacupuncture on retinal nerve growth factor and brain-derived neurotrophic factor expression in a rat model of retinitis pigmentosa.

Authors:  Lucia Pagani; Luigi Manni; Luigi Aloe
Journal:  Brain Res       Date:  2006-05-11       Impact factor: 3.252

3.  The artificial silicon retina in retinitis pigmentosa patients (an American Ophthalmological Association thesis).

Authors:  Alan Y Chow; Ava K Bittner; Machelle T Pardue
Journal:  Trans Am Ophthalmol Soc       Date:  2010-12

4.  A pilot study of an acupuncture protocol to improve visual function in retinitis pigmentosa patients.

Authors:  Ava K Bittner; Jeffrey M Gould; Andy Rosenfarb; Collin Rozanski; Gislin Dagnelie
Journal:  Clin Exp Optom       Date:  2013-10-29       Impact factor: 2.742

5.  Clinical application of acupuncture in ophthalmology.

Authors:  S Dabov; G Goutoranov; R Ivanova; N Petkova
Journal:  Acupunct Electrother Res       Date:  1985       Impact factor: 0.143

6.  Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial.

Authors:  Robert K Koenekoop; Ruifang Sui; Juliana Sallum; L Ingeborgh van den Born; Radwan Ajlan; Ayesha Khan; Anneke I den Hollander; Frans P M Cremers; Janine D Mendola; Ava K Bittner; Gislin Dagnelie; Ronald A Schuchard; David A Saperstein
Journal:  Lancet       Date:  2014-07-13       Impact factor: 79.321
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.